NO313367B1 - Munnvasksammensetninger, konsentrater og pakninger derav, samt anvendelse til fremstilling av medikamenter - Google Patents
Munnvasksammensetninger, konsentrater og pakninger derav, samt anvendelse til fremstilling av medikamenter Download PDFInfo
- Publication number
- NO313367B1 NO313367B1 NO19991302A NO991302A NO313367B1 NO 313367 B1 NO313367 B1 NO 313367B1 NO 19991302 A NO19991302 A NO 19991302A NO 991302 A NO991302 A NO 991302A NO 313367 B1 NO313367 B1 NO 313367B1
- Authority
- NO
- Norway
- Prior art keywords
- solution
- calcium
- phosphate
- ions
- supersaturated
- Prior art date
Links
- 239000012141 concentrate Substances 0.000 title claims description 53
- 239000000203 mixture Substances 0.000 title claims description 45
- 239000003814 drug Substances 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 239000000243 solution Substances 0.000 claims abstract description 183
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 90
- 210000000214 mouth Anatomy 0.000 claims abstract description 30
- 239000003381 stabilizer Substances 0.000 claims abstract description 30
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 23
- 239000002324 mouth wash Substances 0.000 claims abstract description 18
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 17
- 239000007864 aqueous solution Substances 0.000 claims abstract description 14
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 14
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 14
- 229940051866 mouthwash Drugs 0.000 claims abstract description 14
- 229910019142 PO4 Inorganic materials 0.000 claims description 77
- 235000021317 phosphate Nutrition 0.000 claims description 77
- 239000011575 calcium Substances 0.000 claims description 69
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 67
- 229910052791 calcium Inorganic materials 0.000 claims description 67
- 239000010452 phosphate Substances 0.000 claims description 67
- 238000011282 treatment Methods 0.000 claims description 59
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 53
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 45
- 239000011780 sodium chloride Substances 0.000 claims description 23
- 210000003296 saliva Anatomy 0.000 claims description 22
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 20
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 17
- 201000010927 Mucositis Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000012045 crude solution Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 239000011550 stock solution Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 12
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 11
- 239000001569 carbon dioxide Substances 0.000 claims description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 10
- 230000003902 lesion Effects 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 8
- 210000001185 bone marrow Anatomy 0.000 claims description 8
- 206010013781 dry mouth Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 210000004872 soft tissue Anatomy 0.000 claims description 7
- 208000005946 Xerostomia Diseases 0.000 claims description 6
- 239000012459 cleaning agent Substances 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- -1 orthophosphate ions Chemical class 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 230000036760 body temperature Effects 0.000 claims description 5
- 210000002200 mouth mucosa Anatomy 0.000 claims description 5
- 239000011775 sodium fluoride Substances 0.000 claims description 5
- 235000013024 sodium fluoride Nutrition 0.000 claims description 5
- 229910001415 sodium ion Inorganic materials 0.000 claims description 5
- 206010040047 Sepsis Diseases 0.000 claims description 4
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 230000036269 ulceration Effects 0.000 claims description 4
- 208000019505 Deglutition disease Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 2
- 241000222122 Candida albicans Species 0.000 claims description 2
- 206010007134 Candida infections Diseases 0.000 claims description 2
- 208000003322 Coinfection Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 201000003984 candidiasis Diseases 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000035800 maturation Effects 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 206010037844 rash Diseases 0.000 claims description 2
- 230000010322 reactivation of latent virus Effects 0.000 claims description 2
- 208000003265 stomatitis Diseases 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims 6
- 239000000975 dye Substances 0.000 claims 3
- 238000012856 packing Methods 0.000 claims 3
- 239000003599 detergent Substances 0.000 claims 1
- 208000002925 dental caries Diseases 0.000 abstract description 17
- 229910000389 calcium phosphate Inorganic materials 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 14
- 230000003449 preventive effect Effects 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 12
- 238000004140 cleaning Methods 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 9
- 229910052725 zinc Inorganic materials 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 230000000735 allogeneic effect Effects 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 229910000392 octacalcium phosphate Inorganic materials 0.000 description 6
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000003298 dental enamel Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 4
- 229940112822 chewing gum Drugs 0.000 description 4
- 235000015218 chewing gum Nutrition 0.000 description 4
- 229960003260 chlorhexidine Drugs 0.000 description 4
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 229940098804 peridex Drugs 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000000395 remineralizing effect Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000001680 brushing effect Effects 0.000 description 3
- 150000001669 calcium Chemical class 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940034610 toothpaste Drugs 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000000120 Artificial Saliva Substances 0.000 description 2
- 239000004135 Bone phosphate Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006300 shrink film Polymers 0.000 description 2
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 235000021476 total parenteral nutrition Nutrition 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- OYPRJOBELJOOCE-IGMARMGPSA-N Calcium-40 Chemical compound [40Ca] OYPRJOBELJOOCE-IGMARMGPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 206010067352 Osteoradionecrosis Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002821 anti-nucleating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 208000003822 aplasia of lacrimal and salivary glands Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical class [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 201000002170 dentin sensitivity Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical class [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011368 intensive chemotherapy Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010850 salt effect Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036347 tooth sensitivity Effects 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2657896P | 1996-09-18 | 1996-09-18 | |
| GBGB9619464.2A GB9619464D0 (en) | 1996-09-18 | 1996-09-18 | Compositions |
| PCT/US1997/016125 WO1998011866A1 (fr) | 1996-09-18 | 1997-09-18 | Bain de bouche a base d'ions calcium et phosphate en solution sursaturee |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO991302L NO991302L (no) | 1999-03-17 |
| NO991302D0 NO991302D0 (no) | 1999-03-17 |
| NO313367B1 true NO313367B1 (no) | 2002-09-23 |
Family
ID=26310059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19991302A NO313367B1 (no) | 1996-09-18 | 1999-03-17 | Munnvasksammensetninger, konsentrater og pakninger derav, samt anvendelse til fremstilling av medikamenter |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US5993785A (fr) |
| EP (1) | EP0939613B1 (fr) |
| JP (2) | JP3895388B2 (fr) |
| AT (1) | ATE238761T1 (fr) |
| AU (1) | AU4342497A (fr) |
| CA (1) | CA2266409C (fr) |
| DE (1) | DE69721556T2 (fr) |
| DK (1) | DK0939613T3 (fr) |
| ES (1) | ES2197364T3 (fr) |
| GB (1) | GB2318977B (fr) |
| NO (1) | NO313367B1 (fr) |
| PT (1) | PT939613E (fr) |
| WO (1) | WO1998011866A1 (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITFI980051A1 (it) * | 1998-03-06 | 1999-09-06 | Italmed Di Galli Giovanna E Pa | Composizione ad uso odontoiatrico per la desensibilizzazione della dentina esposta |
| NL1018208C2 (nl) * | 2001-06-05 | 2002-12-10 | Calcio B V | Tandpasta. |
| CN1803147B (zh) * | 2001-12-11 | 2010-08-04 | 王小兵 | 缓冲剂对牙菌斑酸化的作用 |
| EP1607005B1 (fr) * | 2001-12-11 | 2008-10-08 | Xiao Bing Wang | L'effect d'un agent tampon à l'acidification de plaque |
| TWI231182B (en) * | 2001-12-11 | 2005-04-21 | Shinkatsu Morisawa | The effect of a buffering agent on acidogenesis of plaque |
| US6610275B1 (en) * | 2002-02-13 | 2003-08-26 | Joseph L. Owades | Device for treating drinking water to make it hostile to dental plaque |
| US9011823B2 (en) | 2005-02-01 | 2015-04-21 | Ada Foundation | Enhanced anti-carious dentifrices, rinses, lozenges, candies and chewing gums and methods of using same |
| US20080299182A1 (en) * | 2007-03-01 | 2008-12-04 | Shuyuan Zhang | Methods and formulations for topical gene therapy |
| US20100178273A1 (en) * | 2007-06-20 | 2010-07-15 | Actogenix Nv Corporation | Methods and compositions for treating mucositis |
| WO2009146104A1 (fr) * | 2008-04-02 | 2009-12-03 | Accentia Biopharmaceuticals, Inc. | Formulations, dispositifs et procédés pour traiter et prévenir une mucosite |
| US20110086108A1 (en) * | 2009-10-12 | 2011-04-14 | Bartholomew Weldon | Dissolving powders that can be mixed with water and used as an oral rinse |
| WO2011109919A1 (fr) | 2010-03-09 | 2011-09-15 | Unilever Plc | Compositions stables de soins buccaux |
| WO2012135426A2 (fr) * | 2011-03-29 | 2012-10-04 | New York University | Compositions antibactériennes et minéralisantes de phosphate de calcium |
| WO2012156502A2 (fr) | 2011-05-18 | 2012-11-22 | Arcoral Pharma As | Préparation de type bain de bouche à deux composants |
| WO2012164083A1 (fr) | 2011-06-01 | 2012-12-06 | Actogenix N.V. | Système d'expression polycistronique pour des bactéries |
| CA2891362C (fr) | 2012-11-16 | 2020-04-21 | Arcoral Pharma As | Comprime effervescent |
| US9433644B2 (en) | 2013-07-25 | 2016-09-06 | Rutgilli Pharmaceuticals, Llc | Formulations and methods for treating oral inflammation, injury, or pain |
| JP5764712B1 (ja) * | 2014-12-16 | 2015-08-19 | 株式会社松風 | 歯質再生剤 |
| US11590165B2 (en) * | 2014-12-17 | 2023-02-28 | Bausch Health Companies Inc. | Formulations of calcium and phosphate for oral inflammation |
| EP3368163B1 (fr) * | 2015-10-26 | 2022-08-17 | Colgate-Palmolive Company | Produits pour bains de bouche et procédés |
| BR112018010091A2 (pt) | 2015-11-19 | 2019-02-05 | Fantarella & Harewood LLC | colutório não alcoólico e método para inibir o crescimento de células de bactérias na boca |
| EP3919065B9 (fr) | 2016-01-14 | 2024-01-24 | Intrexon Actobiotics NV | Compositions et procédés de traitement du diabète de type 1 |
| CN109310587A (zh) * | 2016-04-28 | 2019-02-05 | 加利福尼亚大学董事会 | 用于控制菌斑形成的组合物 |
| AU2017319707B2 (en) | 2016-09-02 | 2023-11-09 | Intrexon Actobiotics N.V. | Genetically modified bacteria stably expressing IL-10 and insulin |
| EP3512872A1 (fr) | 2016-09-13 | 2019-07-24 | Intrexon Actobiotics NV | Micro-organisme muco-adhésif |
| WO2018199749A1 (fr) * | 2017-04-25 | 2018-11-01 | Nutreco Nederland B.V. | Composition contenant un sel chloré destinée à être utilisée chez des animaux en gestation |
| US11642199B2 (en) * | 2018-09-24 | 2023-05-09 | 3M Innovative Properties Company | Dental appliance with cosmetic therapeutic aqueous solution |
| WO2021059240A1 (fr) | 2019-09-27 | 2021-04-01 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Traitement de la maladie cœliaque |
| US11903992B2 (en) * | 2021-01-23 | 2024-02-20 | Cellix Bio Private Limited | Composition comprising lidocaine, l-carnosine and dexpanthenol |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1492247A1 (de) * | 1964-03-20 | 1969-11-06 | Warner Lambert Pharmaceutical | Verfahren zum Wiederverhaerten von Zahnschmelz und dafuer geeignetes Zahnpflegemittel |
| US3679360A (en) * | 1970-06-26 | 1972-07-25 | Nasa | Process for the preparation of brushite crystals |
| GB1408922A (en) * | 1972-02-02 | 1975-10-08 | Blendax Werke Schneider Co | Process and composition for the remineralisation and prevention of demineralisation of human teeth |
| US4108980A (en) * | 1973-01-11 | 1978-08-22 | Colgate-Palmolive Company | Process of preparing materials having calcium and phosphate components |
| US4048300A (en) * | 1973-01-11 | 1977-09-13 | Colgate-Palmolive Company | Dental preparation containing materials having calcium and phosphate components |
| DE2452969A1 (de) * | 1973-11-13 | 1975-05-15 | Procter & Gamble | Mittel zum remineralisieren von zahnschmelz |
| US4080440A (en) * | 1974-12-13 | 1978-03-21 | The Procter & Gamble Company | Method for remineralizing tooth enamel |
| US4097588A (en) * | 1975-03-11 | 1978-06-27 | National Research Development Corporation | Mineralizing dental mouthrinse |
| US4083955A (en) * | 1975-04-02 | 1978-04-11 | The Procter & Gamble Company | Processes and compositions for remineralization of dental enamel |
| GB1509977A (en) * | 1975-10-31 | 1978-05-10 | Nat Res Dev | Remineralising composition |
| US4097935A (en) * | 1976-07-21 | 1978-07-04 | Sterling Drug Inc. | Hydroxylapatite ceramic |
| US4183915A (en) * | 1978-10-13 | 1980-01-15 | Colgate-Palmolive Company | Stable solution for dental remineralization |
| US4177258A (en) * | 1978-10-13 | 1979-12-04 | Colgate Palmolive Company | Dentifrice for dental remineralization |
| US4348381A (en) * | 1981-05-06 | 1982-09-07 | Colgate-Palmolive Company | Dental remineralization composition |
| US4606912A (en) * | 1981-07-22 | 1986-08-19 | Caries Research Group Of Rochester, Inc. | Method of making a clear, stable aqueous mouthwash solution and the solution made by that method for the enhancement of cells of the oral cavity and the remineralization of teeth |
| US4532124A (en) * | 1981-08-19 | 1985-07-30 | Development Finance Corporation Of New Zealand | Dental rinse |
| US5460803A (en) * | 1989-05-24 | 1995-10-24 | American Dental Association Health Foundation | Methods and compositions for mineralizing and fluoridating calcified tissues |
| US5037639A (en) * | 1989-05-24 | 1991-08-06 | American Dental Association Health Foundation | Methods and compositions for mineralizing calcified tissues |
| US5427768A (en) * | 1993-06-23 | 1995-06-27 | American Dental Association Health Foundation | Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use |
| US5658554A (en) | 1995-06-01 | 1997-08-19 | Colgate-Palmolive Company | Mouth moistener for the relief of dry mouth condition |
| US5605675A (en) * | 1995-06-06 | 1997-02-25 | Enamelon Inc. | Processes and compositions for remineralization and prevention of demineralization of dental enamel |
| US5603922A (en) * | 1995-08-08 | 1997-02-18 | Enamelon Inc. | Processes and compositions for the remineralization of teeth |
| US5571502A (en) * | 1995-08-08 | 1996-11-05 | Enamelon Research | Stable single-part compositions and the use thereof for remineralization of lesions in teeth |
-
1997
- 1997-09-18 JP JP51475898A patent/JP3895388B2/ja not_active Expired - Lifetime
- 1997-09-18 ES ES97941536T patent/ES2197364T3/es not_active Expired - Lifetime
- 1997-09-18 WO PCT/US1997/016125 patent/WO1998011866A1/fr active IP Right Grant
- 1997-09-18 EP EP97941536A patent/EP0939613B1/fr not_active Expired - Lifetime
- 1997-09-18 US US08/933,481 patent/US5993785A/en not_active Expired - Lifetime
- 1997-09-18 AT AT97941536T patent/ATE238761T1/de active
- 1997-09-18 AU AU43424/97A patent/AU4342497A/en not_active Abandoned
- 1997-09-18 PT PT97941536T patent/PT939613E/pt unknown
- 1997-09-18 DE DE69721556T patent/DE69721556T2/de not_active Expired - Lifetime
- 1997-09-18 CA CA002266409A patent/CA2266409C/fr not_active Expired - Lifetime
- 1997-09-18 GB GB9719780A patent/GB2318977B/en not_active Expired - Lifetime
- 1997-09-18 DK DK97941536T patent/DK0939613T3/da active
-
1999
- 1999-03-17 NO NO19991302A patent/NO313367B1/no not_active IP Right Cessation
- 1999-07-09 US US09/350,965 patent/US6387352B1/en not_active Expired - Lifetime
-
2002
- 2002-05-14 US US10/146,500 patent/US20030152530A1/en not_active Abandoned
-
2006
- 2006-02-21 JP JP2006043285A patent/JP4746441B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69721556T2 (de) | 2004-03-04 |
| ES2197364T3 (es) | 2004-01-01 |
| EP0939613A1 (fr) | 1999-09-08 |
| DK0939613T3 (da) | 2003-07-14 |
| JP3895388B2 (ja) | 2007-03-22 |
| ATE238761T1 (de) | 2003-05-15 |
| AU4342497A (en) | 1998-04-14 |
| JP2001500874A (ja) | 2001-01-23 |
| US5993785A (en) | 1999-11-30 |
| US6387352B1 (en) | 2002-05-14 |
| DE69721556D1 (de) | 2003-06-05 |
| JP4746441B2 (ja) | 2011-08-10 |
| NO991302L (no) | 1999-03-17 |
| US20020044910A1 (en) | 2002-04-18 |
| GB9719780D0 (en) | 1997-11-19 |
| GB2318977B (en) | 1999-07-21 |
| JP2006199702A (ja) | 2006-08-03 |
| GB2318977A (en) | 1998-05-13 |
| WO1998011866A1 (fr) | 1998-03-26 |
| PT939613E (pt) | 2003-07-31 |
| NO991302D0 (no) | 1999-03-17 |
| EP0939613B1 (fr) | 2003-05-02 |
| CA2266409A1 (fr) | 1998-03-26 |
| CA2266409C (fr) | 2009-01-06 |
| US20030152530A1 (en) | 2003-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO313367B1 (no) | Munnvasksammensetninger, konsentrater og pakninger derav, samt anvendelse til fremstilling av medikamenter | |
| US20080031831A1 (en) | Oral anti-calculus compositions and methods of use thereof | |
| US20100303737A1 (en) | Tooth-Cleaning Formulation | |
| Y. Miller et al. | Topical fluoride for preventing dental caries in children and adolescents | |
| CA2971909A1 (fr) | Composition dentaire anti-tartre et son procede d'utilisation | |
| CN115916352A (zh) | 口腔护理组合物 | |
| CN104042780A (zh) | 一种口腔护理液 | |
| WO2014036564A1 (fr) | Composition de soin buccal pour la promotion et le maintien de la santé buccale et procédé de formation et d'utilisation associé | |
| WO2020095099A1 (fr) | Composition cosmétique pour le soin de la cavite buccale | |
| CN102525833A (zh) | 一种防龋漱口水组合物 | |
| Mellberg et al. | Fluoride concentrations in deciduous teeth of children using fluoride mouthrinses | |
| RU2068688C1 (ru) | Лечебно-профилактическая зубная паста "фортуна" | |
| US20180028843A1 (en) | Compositions for human dental care | |
| AU2019100472A4 (en) | Methods and compositions for treating gingivitis and inflammation and reducing plaque and tartar | |
| GB2329836A (en) | Mouthwash compositions and their preparation | |
| US20220062125A1 (en) | Multipurpose fluorinated biphosphate toothpaste composition | |
| Pranitha et al. | SDF: Enhanced preventive, operative care: Call based on caries risk | |
| Rajan et al. | Silver Diamine Fluoride: A Magical Tool in Caries Management | |
| WO2024138270A1 (fr) | Compositions de soins buccaux ingérables et leurs utilisations | |
| WO1987003476A1 (fr) | Composition pour le traitement de la maladie du periodonte | |
| Ferris | Comparing the Efficacy of Sodium Fluoride and Silver Diamine Fluoride in Arresting Caries through Statistical Analysis | |
| Sampaio et al. | BOOSTING FLUORIDE-TOOTHPASTES WITH NON-FLUORIDE AGENTS FOR CARIES CONTROL. | |
| CN112691045A (zh) | 一种抗菌牙膏及其制备方法 | |
| CN113855583A (zh) | 一种苯酚牙膏及其制作方法 | |
| KR20020028765A (ko) | 생약추출물과 키토산을 함유한 치주 질환 예방을 위한치약조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |